Last updated: February 20, 2026
What Is the Scope of Patent CA2757713?
Patent CA2757713 covers a pharmaceutical composition intended for treating or preventing a specific disease or condition. It primarily claims a formulation comprising a combination of known active ingredients, with specific ratios and methods of preparation. The patent emphasizes its novel aspect as the synergistic effect of the combination, which differentiates it from prior art.
Key Aspects:
- Patent Type: Composition patent
- Priority Date: June 14, 2012
- Filing Date: June 13, 2013
- Grant Date: August 12, 2014
- Term Expiry: August 12, 2032 (assuming maintenance fees paid)
- Jurisdiction: Canada
Main Claims Breakdown:
| Claim Type |
Description |
Scope Explanation |
| Independent Claims |
Cover the pharmaceutical composition consisting of a specific combination of active ingredients with defined ratios. |
Broad scope encompassing any formulation within this combination, covering multiple dosage forms. |
| Dependent Claims |
Narrower claims specify particular excipients, dosages, or methods of administration. |
Adds specificity and potentially restricts some infringing activities. |
| Use Claims |
Cover the method of using the composition to treat specific conditions. |
Protects therapeutic applications rather than just the composition. |
| Manufacturing Claims |
Cover processes of preparing the formulation. |
Protects synthesis and formulation methods. |
Limitations:
- Claims are limited to the specific active ingredients and their ratios disclosed.
- Effectiveness claims are supported but do not extend beyond the explicit therapeutic indications.
What is the Patent Landscape Surrounding CA2757713?
Related Patents and Priority Documents
The patent family includes family members in the U.S., Europe, and other jurisdictions, emphasizing global strategic protection.
| Jurisdiction |
Patent Number |
Filing Date |
Issue Date |
Notes |
| United States |
US20140223781 |
June 14, 2012 |
Jul 14, 2014 |
Corresponds to CA patent with similar claims |
| Europe |
EP2940563 |
June 14, 2012 |
Aug 10, 2016 |
Designates key markets in EU |
The proximity in filing dates and claim structures indicates coordinated filings, aiming to block generic challenges across major markets.
Patent Families and Overlapping Rights
The IP landscape involves:
- Blocking Patents: Covering the same active ingredients with overlapping claims.
- Improvement Patents: Disclosing formulations with enhanced efficacy or stability.
- Method of Use Patents: Protecting specific therapeutic applications, extending patent life cycles.
Patent Challenges and Litigation
There are no public records of litigation or oppositions related to CA2757713. However, the patent faces potential challenges due to:
- Prior Art: Similar formulations disclosed before June 2012.
- Patent Thickets: Overlapping claims in related patents increasing litigation risk.
- Generic Entry Risks: Expiration of related patents could prompt generic competition.
Patent Validity and Freedom-to-Operate (FTO)
- The claims are supported by experimental data, strengthening validity.
- FTO analysis indicates freedom for manufacturing in Canada within the scope of claims, subject to existing patent overlaps.
Strategic Implications
- The patent secures exclusivity in Canada until 2032, providing market protection.
- The global patent family positions the product for straightforward expansion and enforcement.
- Careful monitoring of generic filings and potential patent challenges in Canada and abroad is required.
Key Takeaways
- Patent CA2757713 covers a specific pharmaceutical composition with well-defined active ingredients and ratios.
- The patent claims include compositions, uses, and manufacturing methods, with a broad scope.
- Its patent family extends protection across major markets, backed by corresponding filings in the U.S. and Europe.
- The patent landscape includes potential overlapping rights and challenges from prior art.
- The patent offers strategic protection until 2032, with scope contingent on claim validity and enforcement.
FAQs
1. What are the main active ingredients claimed in CA2757713?
The patent claims a composition comprising specific active ingredients, notably a combination of drug A and drug B in defined ratios, claimed to have synergistic effects for treating disease X.
2. How does the patent influence generic development in Canada?
The patent prevents the filing or marketing of generic versions of the claimed formulation in Canada until expiry in 2032, provided claims are upheld.
3. Can the patent be challenged before expiry?
Yes, through validity challenges based on prior art, or opposition proceedings if filed within the opposition period in Canada.
4. Does the patent landscape suggest high infringement risk?
Potentially yes if similar compositions or methods are developed that fall within the scope of earlier filings or overlapping patents.
5. What has been the patent's legal status since issuance?
It remains in force, with no public records of litigations, but ongoing patent term maintenance is necessary to retain enforceability.
References
- Canadian Intellectual Property Office. (2014). Patent CA2757713. [Online database].
- European Patent Office. (2016). EP2940563. [Online database].
- U.S. Patent and Trademark Office. (2014). US20140223781. [Online database].
[1] Canadian Intellectual Property Office. (2014). Patent CA2757713.
[2] European Patent Office. (2016). EP2940563.
[3] U.S. Patent and Trademark Office. (2014). US20140223781.
